Phase III Clinical Study of JTE-052A - 52-week Long-term Study in Patients with Atopic Dermatitis -
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2018
At a glance
- Drugs Delgocitinib (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Japan Tobacco
- 13 Nov 2018 Status changed from active, no longer recruiting to completed.
- 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 12 May 2017 New trial record